Literature DB >> 10935647

Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis.

M D Kraus1, J Haley.   

Abstract

Distinction of lymphocyte predominance Hodgkin's disease (LPHD) from other forms of lymphoma often requires immunohistochemistry (IHC). Most previously published recommended panels include markers to define the large neoplastic cells (for example, CD20, J chain, CD45) as well as the non-neoplastic background cells (CD21, CD45RO, CD57, TiA 1). In the present study we examine the practical use of a double IHC method designed to look simultaneously at two germinal center specific cell types: bcl6+ cells and [bc16+, CD57+] co-positive cells. All 10 nodular LPHD had bcl6+ large cells and numerous CD57+ small background cells, including [bcl6+CD57+] cells in rosettes. One case of LPHD with large cell transformation contained numerous bcl6+ large cells both singly (in areas of typical LPHD) and in sheets (in foci of large cell transformation), many CD57+ small cells but few [bcl6+CD57+] co-positive cells and no rosettes. In none of the five cases of florid progressive transformation of germinal centers were true rosettes seen, although all contained variable numbers of bcl6+ large cells and CD57+ cells. Lymphocyte-rich classic Hodgkin's disease LRCHD cases were notable for bcl6 reactivity in Reed-Sternberg cells in all cases, numerous background small bcl6+ lymphocytes, and rare CD57+ cells. Two phenotypic profiles were associated with the 10 cases of T cell-rich B cell large cell lymphoma (TCRBCL). In the first, group "A," six of six cases had bc16- large cells and few CD57+ small cells, and none had significant numbers of [bcl6+, CD57+] co-positive cells. In the second, group "B," four of four cases had bcl6+ large cells with numerous CD57+ and [bcl6+, CD57+] co-positive cells. These findings not only show that LPHD can be distinguished from its morphologic mimics through identification of specific germinal center cell types, but also identifies a second group of TCRBCL (group "B") whose phenotype suggests it might be an architectural variant of nodular LPHD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935647     DOI: 10.1097/00000478-200008000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 2.  Follicular helper T cells: implications in neoplastic hematopathology.

Authors:  Philippe Gaulard; Laurence de Leval
Journal:  Semin Diagn Pathol       Date:  2011-08       Impact factor: 3.464

Review 3.  Hodgkin's lymphoma: the pathologist's viewpoint.

Authors:  S A Pileri; S Ascani; L Leoncini; E Sabattini; P L Zinzani; P P Piccaluga; A Pileri; M Giunti; B Falini; G B Bolis; H Stein
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

4.  Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.

Authors:  S Montes-Moreno
Journal:  Adv Hematol       Date:  2010-10-24

5.  CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Ahmad Sattarzadeh; Arjan Diepstra; Bea Rutgers; Anke van den Berg; Lydia Visser
Journal:  Exp Hematol Oncol       Date:  2015-09-15

6.  Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?

Authors:  Sylvia Hartmann; Claudia Döring; Christina Jakobus; Benjamin Rengstl; Sebastian Newrzela; Thomas Tousseyn; Xavier Sagaert; Maurilio Ponzoni; Fabio Facchetti; Chris de Wolf-Peeters; Christian Steidl; Randy Gascoyne; Ralf Küppers; Martin-Leo Hansmann
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.